Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 1
1967 4
1968 5
1969 5
1970 5
1971 6
1972 12
1973 14
1974 13
1975 9
1976 9
1977 3
1978 7
1979 9
1980 12
1981 6
1982 19
1983 14
1984 10
1985 14
1986 17
1987 13
1988 20
1989 21
1990 36
1991 23
1992 20
1993 31
1994 25
1995 40
1996 36
1997 38
1998 44
1999 50
2000 64
2001 69
2002 60
2003 65
2004 76
2005 67
2006 90
2007 85
2008 85
2009 85
2010 91
2011 103
2012 110
2013 120
2014 122
2015 120
2016 112
2017 134
2018 107
2019 116
2020 124
2021 128
2022 118
2023 102
2024 52

Text availability

Article attribute

Article type

Publication date

Search Results

2,707 results

Results by year

Filters applied: . Clear all
Page 1
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Douglas RS, et al. N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434. N Engl J Med. 2020. PMID: 31971679 Clinical Trial.
Prespecified secondary outcomes at week 24 were an overall response (a reduction of 2 points in the Clinical Activity Score plus a reduction in proptosis of 2 mm), a Clinical Activity Score of 0 or 1 (indicating no or minimal inflammation), the mean change in propto …
Prespecified secondary outcomes at week 24 were an overall response (a reduction of 2 points in the Clinical Activity Score plus a re …
Future Projections in Thyroid Eye Disease.
Barbesino G, Salvi M, Freitag SK. Barbesino G, et al. J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S47-S56. doi: 10.1210/clinem/dgac252. J Clin Endocrinol Metab. 2022. PMID: 36346684 Free PMC article. Review.
Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, clinical activity score, diplopia, and quality of life in patients with active TED, with good tolerability. Newly proposed TED …
Recently, teprotumumab, an insulin-like growth factor 1 receptor (IGF-1R) inhibitor, has demonstrated significant improvement in proptosis, …
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Rhee TG, et al. JAMA Psychiatry. 2022 Dec 1;79(12):1162-1172. doi: 10.1001/jamapsychiatry.2022.3352. JAMA Psychiatry. 2022. PMID: 36260324 Free PMC article.
Two authors also manually and independently searched all relevant studies in US and European clinical trial registries and Google Scholar. STUDY SELECTION: Included were studies that involved (1) a diagnosis of depression using standardized diagnostic criteria, (2) …
Two authors also manually and independently searched all relevant studies in US and European clinical trial registries and Goo …
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marinò M, Antonelli A, Eckstein A, Führer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ. Douglas RS, et al. Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21. Ophthalmology. 2022. PMID: 34688699 Free article. Clinical Trial.
DESIGN: The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X) is a teprotumumab treatment and re-treatment trial following the placebo-controlled teprotumumab Phase 3 Treatment of Gra …
DESIGN: The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an Open-Label Clinical Extension Stud …
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability.
Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Roberti R, et al. CNS Drugs. 2021 Jun;35(6):609-618. doi: 10.1007/s40263-021-00819-8. Epub 2021 May 16. CNS Drugs. 2021. PMID: 33993416 Review.
The recommended starting dose is 12.5 mg/day, titrated gradually to the target daily dose of 200 mg, which may be increased to a maximum of 400 mg/day based on clinical response. Although the high rate of seizure freedom observed in randomized, placebo-controlled …
The recommended starting dose is 12.5 mg/day, titrated gradually to the target daily dose of 200 mg, which may be increased to a maximum of …
Editor's Comment.
Nuijts RMMA, Saelens IEY, Bauer NJC. Nuijts RMMA, et al. J Cataract Refract Surg. 2018 Sep;44(9):1163. doi: 10.1016/j.jcrs.2018.07.039. J Cataract Refract Surg. 2018. PMID: 30165945 No abstract available.
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.
We aimed to investigate the safety and efficacy of rituximab, an anti-CD20 monoclonal antibody, against relapses in patients with NMOSD. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled clinical trial at eight hospitals in Japan. .. …
We aimed to investigate the safety and efficacy of rituximab, an anti-CD20 monoclonal antibody, against relapses in patients with NMOSD. MET …
Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy.
Barbieri MA, Perucca E, Spina E, Rota P, Franco V. Barbieri MA, et al. CNS Neurol Disord Drug Targets. 2023;22(3):394-403. doi: 10.2174/1871527321666220113110044. CNS Neurol Disord Drug Targets. 2023. PMID: 35049441 Review.
Cenobamate is a CYP2C19 inhibitor and an inducer of CYP3A4 and CYP2B6, and consequently, it can cause a number of drug-drug interactions. Efficacy and safety have been evaluated in two randomized, double-blind, placebo-controlled adjunctive therapy trials in adults with fo …
Cenobamate is a CYP2C19 inhibitor and an inducer of CYP3A4 and CYP2B6, and consequently, it can cause a number of drug-drug interactions. Ef …
The Non-surgical Management of Ophthalmoplegia.
Arnoldi K. Arnoldi K. J Binocul Vis Ocul Motil. 2018 Jan-Mar;68(1):24-27. doi: 10.1080/2576117X.2017.1418459. Epub 2018 Jan 17. J Binocul Vis Ocul Motil. 2018. PMID: 30196779 Review.
Ophthalmoplegia can result from damage or dysfunction of the supranuclear eye movement pathways, the brainstem internuclear pathways, or the ocular motor nerves. Diplopia and impaired eye movements are commonly associated symptoms. ...They may accelerate recovery for those …
Ophthalmoplegia can result from damage or dysfunction of the supranuclear eye movement pathways, the brainstem internuclear pathways, or the …
Diplopia after Strabismus Surgery.
Sharma M, Hunter DG. Sharma M, et al. Semin Ophthalmol. 2018;33(1):102-107. doi: 10.1080/08820538.2017.1353827. Epub 2017 Dec 1. Semin Ophthalmol. 2018. PMID: 29193991 Review.
Diplopia is a disappointing and, at times, unanticipated consequence of what might otherwise be considered anatomically successful strabismus surgery. In this study, we review the existing literature regarding diplopia after strabismus surgery in the context of the …
Diplopia is a disappointing and, at times, unanticipated consequence of what might otherwise be considered anatomically successful st …
2,707 results